{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:10:43Z","timestamp":1770894643944,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijrobp.2023.10.015","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T11:03:54Z","timestamp":1697886234000},"page":"986-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging\u2013Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial"],"prefix":"10.1016","volume":"118","author":[{"given":"Beth K.","family":"Neilsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting Martin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wisdom O.","family":"Akingbemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Neylon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca F.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4836-8483","authenticated-orcid":false,"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.10.015_bib0001","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1525-1497.2000.90842.x","article-title":"Treatment decisions for localized prostate cancer: Asking men what's important","volume":"15","author":"Holmboe","year":"2000","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0002","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0003","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1464-410X.2010.09833.x","article-title":"Early prostate cancer\u2014Which treatment do men prefer and why?","volume":"107","author":"Anandadas","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0005","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.2017.1652","article-title":"Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer","volume":"317","author":"Chen","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0006","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0007","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0008","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0009","article-title":"Effect of standard versus dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial","volume":"14","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0011","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0012","first-page":"6373","article-title":"Late toxicity rates following definitive radiotherapy for prostate cancer","volume":"19","author":"Ohri","year":"2012","journal-title":"Can J Urol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0013","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clon.2017.03.006","article-title":"Late genitourinary toxicity outcomes in 300 prostate cancer patients treated with dose-escalated image-guided intensity-modulated radiotherapy","volume":"29","author":"Byrne","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.juro.2012.08.091","article-title":"Severe genitourinary toxicity following radiation therapy for prostate cancer\u2014How long does it last?","volume":"189","author":"Kim","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0016","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2021.03.017","article-title":"Quality of life after prostate cancer treatment","volume":"110","author":"Kishan","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0017","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0018","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"The fraction size sensitivity of late genitourinary toxicity: Analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0019","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2015.10.003","article-title":"Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models","volume":"117","author":"Yahya","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2016.01.013","article-title":"Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy","volume":"119","author":"Thor","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","article-title":"Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs 78 Gy): Relationships with local dose, acute effects, and baseline characteristics","volume":"78","author":"Heemsbergen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2010.08.002","article-title":"The relationship between external beam radiotherapy dose and chronic urinary dysfunction\u2014A methodological critique","volume":"97","author":"Rosewall","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0023","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ijrobp.2018.08.015","article-title":"A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy","volume":"102","author":"Olsson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0024","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clon.2018.05.001","article-title":"An investigation of dosimetric correlates of acute toxicity in prostate stereotactic body radiotherapy: Dose to urinary trigone is associated with acute urinary toxicity","volume":"30","author":"Henderson","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0167-8140(15)40728-5","article-title":"PO-0736: Bladder and trigone surface doses are related to acute urinary toxicity in focally dose-escalated prostate IMRT","volume":"115","author":"Murray","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0026","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: Implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197757","article-title":"Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients","volume":"13","author":"Schaake","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0029","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2004.12.068","article-title":"Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity","volume":"62","author":"Allen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/128360","article-title":"An NTCP analysis of urethral complications from low doserate mono- and bi-radionuclide brachytherapy","volume":"2011","author":"Nuttens","year":"2011","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0031","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.prro.2013.02.011","article-title":"Dosimetric analysis of radiation therapy oncology group 0321: The importance of urethral dose","volume":"4","author":"Hsu","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0032","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brachy.2019.12.001","article-title":"A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy","volume":"19","author":"Lu","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0033","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.ijrobp.2020.07.019","article-title":"Rectal and urethro-vesical subregions for toxicity prediction after prostate cancer radiotherapy: Validation of voxel-based models in an independent population","volume":"108","author":"Mylona","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0034","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.eururo.2008.06.048","article-title":"Characteristics of spontaneous activity in the bladder trigone","volume":"56","author":"Roosen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0036","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","article-title":"Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): A phase III randomized trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0037","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0038","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0039","unstructured":"US Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Available at: https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf. Accessed November 15, 2022."},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0040","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0041","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0042","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0043","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12859-019-2610-2","article-title":"BPG: Seamless, automated and interactive visualization of scientific data","volume":"20","author":"P'ng","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ijrobp.2023.10.015_bib0044","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623080215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623080215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:10:15Z","timestamp":1759745415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623080215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0360301623080215"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.10.015","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging\u2013Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}